Thus, in the bustling era for RAS-RAF-MAPK targeting molecules, the KRAS and RAS-MAPK signaling represents a crucial therapeutic target in mature B cell neoplasms that must be completely exploited. Here, RAF1 is linked to B-cell neoplasm.